文献速递哮喘

基于血嗜酸性粒细胞和呼出气一氧化氮的哮喘发作风险量表原型推导

Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide.
PubMed 文献 · Thorax · 2021-08-06

该研究从Novel START、CAPTAIN、QUEST等8项试验的对照组中提取生物标志物分层的发作率(n=3051),推导率比和预测哮喘发作率,构建以血嗜酸性粒细胞计数和呼出气一氧化氮(FeNO)为基础的原型风险量表,显示其预测哮喘发作的潜力,发作可能通过抗炎治疗预防。

要点

  • 基于血嗜酸性粒细胞和FeNO的原型风险量表可预测哮喘发作。
  • 数据来源于8项试验对照组共3051例患者的生物标志物分层发作率。
  • 该量表提示抗炎治疗可能预防哮喘发作。

核心结论

  • 原型风险量表显示预测哮喘发作的潜力,发作可能通过抗炎治疗预防。

研究设计与样本

  • 从Novel START、CAPTAIN、QUEST、Benralizumab Phase 2b、PATHWAY、STRATOS 1-2和DREAM试验的对照组中提取并汇总生物标志物分层的试验水平发作率(n=3051)。

主要发现

  • 基于汇总的发作率推导率比和不同患者组的预测哮喘发作率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Reduction of the risk of asthma attacks is a major goal of current asthma management. We propose to derive a risk scale predicting asthma attacks based on the blood eosinophil count and exhaled nitric oxide (FeNO). Biomarker-stratified trial-level attack rates were extracted and pooled from the control arms of the Novel START, CAPTAIN, QUEST, Benralizumab Phase 2b, PATHWAY, STRATOS 1-2 and DREAM trials (n=3051). These were used to derive rate ratios and the predicted asthma attack rate for different patient groups. The resultant prototype risk scale shows potential to predict asthma attacks, which may be prevented by anti-inflammatory treatment.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Couillard S, Laugerud A, Jabeen M, et al. Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. Thorax. 2021. PMID: 34362839. doi:10.1136/thoraxjnl-2021-217325

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。